Cover Image

PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): a pooled analysis

© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: NIVO + IPI and NIVO showed superior clinical activity vs IPI in a phase 3 trial of MEL patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Long, Georgina (Author) , Hassel, Jessica C. (Author)
Format: Article (Journal)
Language:English
Published: 11 October 2016
In: Annals of oncology
Year: 2016, Volume: 27
ISSN:1569-8041
DOI:10.1093/annonc/mdw379.07
Online Access:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1093/annonc/mdw379.07
Verlag, kostenfrei, Volltext: https://academic.oup.com/annonc/article/27/suppl_6/1112PD/2799923
Get full text
Author Notes:G.V. Long, J. Larkin, P.A. Ascierto, F.S. Hodi, P. Rutkowski, V. Sileni, J. Hassel, C. Lebbe, A.C. Pavlick, J. Wagstaff, D. Schadendorf, R. Dummer, D. Hogg, J.B. a. G. Haanen, P. Corrie, C. Hoeller, C. Horak, J. Wolchok, C. Robert

MARC

LEADER 00000caa a2200000 c 4500
001 1565243943
003 DE-627
005 20220814020748.0
007 cr uuu---uuuuu
008 171110s2016 xx |||||o 00| ||eng c
024 7 |a 10.1093/annonc/mdw379.07  |2 doi 
035 |a (DE-627)1565243943 
035 |a (DE-576)495243949 
035 |a (DE-599)BSZ495243949 
035 |a (OCoLC)1340981884 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Long, Georgina  |e VerfasserIn  |0 (DE-588)1143993705  |0 (DE-627)100383440X  |0 (DE-576)495243779  |4 aut 
245 1 0 |a PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL)  |b a pooled analysis  |c G.V. Long, J. Larkin, P.A. Ascierto, F.S. Hodi, P. Rutkowski, V. Sileni, J. Hassel, C. Lebbe, A.C. Pavlick, J. Wagstaff, D. Schadendorf, R. Dummer, D. Hogg, J.B. a. G. Haanen, P. Corrie, C. Hoeller, C. Horak, J. Wolchok, C. Robert 
264 1 |c 11 October 2016 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 10.11.2017 
520 |a © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: NIVO + IPI and NIVO showed superior clinical activity vs IPI in a phase 3 trial of MEL patients (pts), irrespective of PD-L1 tumor expression. Among pts with high PD-L1 expression (≥5%), median progression-free survival (mPFS) was similar between NIVO + IPI and NIVO, but overall response rate (ORR) was higher with NIVO + IPI. We describe PD-L1 as a biomarker for NIVO + IPI and NIVO efficacy across phase 2 (CheckMate 069) and phase 3 (CheckMate 066 and 067) trials.Methods: Treatment-naïve pts (N = 832) with MEL received NIVO 1 mg/kg + IPI 3 mg/kg Q3W × 4 or NIVO 3 mg/kg Q2W, followed by NIVO 3 mg/kg Q2W until progression or unacceptable toxicity. Tumor tissue from primary or metastatic sites,... 
700 1 |a Hassel, Jessica C.  |d 1975-  |e VerfasserIn  |0 (DE-588)129790702  |0 (DE-627)480399069  |0 (DE-576)29783715X  |4 aut 
773 0 8 |i Enthalten in  |t Annals of oncology  |d Amsterdam [u.a.] : Elsevier, 1990  |g 27(2016,Supplement 6) Artikel-Nummer 1112PD, 1 Seite  |h Online-Ressource  |w (DE-627)320428796  |w (DE-600)2003498-2  |w (DE-576)098134345  |x 1569-8041  |7 nnas  |a PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL) a pooled analysis 
773 1 8 |g volume:27  |g year:2016  |g supplement:Supplement 6  |a PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL) a pooled analysis 
856 4 0 |u http://dx.doi.org/10.1093/annonc/mdw379.07  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://academic.oup.com/annonc/article/27/suppl_6/1112PD/2799923  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20171110 
993 |a Article 
994 |a 2016 
998 |g 129790702  |a Hassel, Jessica C.  |m 129790702:Hassel, Jessica C.  |d 910000  |d 911300  |e 910000PH129790702  |e 911300PH129790702  |k 0/910000/  |k 1/910000/911300/  |p 7 
999 |a KXP-PPN1565243943  |e 298694518X 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["G.V. Long, J. Larkin, P.A. Ascierto, F.S. Hodi, P. Rutkowski, V. Sileni, J. Hassel, C. Lebbe, A.C. Pavlick, J. Wagstaff, D. Schadendorf, R. Dummer, D. Hogg, J.B. a. G. Haanen, P. Corrie, C. Hoeller, C. Horak, J. Wolchok, C. Robert"]},"origin":[{"dateIssuedDisp":"11 October 2016","dateIssuedKey":"2016"}],"person":[{"display":"Long, Georgina","family":"Long","role":"aut","given":"Georgina"},{"display":"Hassel, Jessica C.","given":"Jessica C.","role":"aut","family":"Hassel"}],"relHost":[{"disp":"PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL) a pooled analysisAnnals of oncology","recId":"320428796","physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"official journal of the European Society for Medical Oncology","title":"Annals of oncology","title_sort":"Annals of oncology"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"origin":[{"publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","dateIssuedKey":"1990","dateIssuedDisp":"1990-"}],"id":{"eki":["320428796"],"issn":["1569-8041"],"zdb":["2003498-2"]},"part":{"year":"2016","text":"27(2016,Supplement 6) Artikel-Nummer 1112PD, 1 Seite","volume":"27"},"pubHistory":["1.1990 -"],"corporate":[{"role":"isb","display":"European Society for Medical Oncology"}]}],"id":{"eki":["1565243943"],"doi":["10.1093/annonc/mdw379.07"]},"title":[{"subtitle":"a pooled analysis","title":"PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL)","title_sort":"PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL)"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 10.11.2017"],"recId":"1565243943"} 
SRT |a LONGGEORGIPDL1EXPRES1120 

Similar Items